Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles

• Published in: Journal of controlled release Vol. 343; pp. 207 - 216
• Main Authors: Evers, Martijn J.W., Du, Wenjuan, Yang, Qiangbing, Kooijmans, Sander A.A., Vink, Aryan, van Steenbergen, Mies, Vader, Pieter, de Jager, Saskia C.A., Fuchs, Sabine A., Mastrobattista, Enrico, Sluijter, Joost P.G., Lei, Zhiyong, Schiffelers, Raymond
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2022
• Subjects: Animals; Infarction; Lipid nanoparticles; Liposomes; Luciferases, Firefly; Mice; Modified mRNA; Myocardial infarction; Myocardium; Nanoparticles; Reperfusion injury; RNA, Messenger; RNA, Small Interfering - genetics; Systemic delivery; Myocardial infarction; Modified mRNA; Systemic delivery; Lipid nanoparticles; Reperfusion injury
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/j.jconrel.2022.01.027

Lipid Nanoparticles (LNPs) are a promising drug delivery vehicle for clinical siRNA delivery. Modified mRNA (modRNA) has recently gained great attention as a therapeutic molecule in cardiac regeneration. However, for mRNA to be functional, it must first reach the diseased myocardium, enter the target cell, escape from the endosomal compartment into the cytosol and be translated into a functional protein. However, it is unknown if LNPs can effectively deliver mRNA, which is much larger than siRNA, to the ischemic myocardium. Here, we evaluated the ability of LNPs to deliver mRNA to the myocardium upon ischemia-reperfusion injury functionally. By exploring the bio-distribution of fluorescently labeled LNPs, we observed that, upon reperfusion, LNPs accumulated in the infarct area of the heart. Subsequently, the functional delivery of modRNA was evaluated by the administration of firefly luciferase encoding modRNA. Concomitantly, a significant increase in firefly luciferase expression was observed in the heart upon myocardial reperfusion when compared to sham-operated animals. To characterize the targeted cells within the myocardium, we injected LNPs loaded with Cre modRNA into Cre-reporter mice. Upon LNP infusion, Tdtomato+ cells, derived from Cre mediated recombination, were observed in the infarct region as well as the epicardial layer upon LNP infusion. Within the infarct area, most targeted cells were cardiac fibroblasts but also some cardiomyocytes and macrophages were found. Although the expression levels were low compared to LNP-modRNA delivery into the liver, our data show the ability of LNPs to functionally deliver modRNA therapeutics to the damaged myocardium, which holds great promise for modRNA-based cardiac therapies. [Display omitted] •Modified mRNA (modRNA) possesses great potential as a therapeutic strategy in cardiac regeneration.•Lipid nanoparticles (LNPs) are promising drug delivery vehicles for clinical modRNA delivery.•Ischemia-reperfusion injury leads to increased vascular permeability, enabling extravasation of lipid nanoparticles.•LNP/modRNA, enriched in the damaged area, can be taken up and translated into functional proteins by different cell types.